Achilles Therapeutics - ACHL Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHL shares.
View ACHL analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1 year price objectives for Achilles Therapeutics' shares. Their ACHL share price forecasts range from $8.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,036.5% from the stock's current price.
View analysts price targets for ACHL or view top-rated stocks among Wall Street analysts.

Achilles Therapeutics' stock was trading at $0.90 at the beginning of 2023. Since then, ACHL shares have decreased by 2.2% and is now trading at $0.8799.
View the best growth stocks for 2023 here.

Achilles Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 6,300 shares, a drop of 33.7% from the February 28th total of 9,500 shares. Based on an average daily volume of 445,400 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's stock are sold short.
View Achilles Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ACHL earnings forecast.

Achilles Therapeutics plc (NASDAQ:ACHL) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.14.

(ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO.

Achilles Therapeutics trades on the NASDAQ under the ticker symbol "ACHL."

Achilles Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (4.11%), Point72 Asset Management L.P. (3.61%), Renaissance Technologies LLC (1.24%), Millennium Management LLC (0.21%), Jane Street Group LLC (0.12%) and Virtu Financial LLC (0.08%).

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACHL stock can currently be purchased for approximately $0.88.

Achilles Therapeutics (NASDAQ:ACHL) has a market capitalization of $36.02 million. The company earns $-71,180,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

The company employs 242 workers across the globe.

Achilles Therapeutics' mailing address is 245 HAMMERSMITH ROAD, LONDON X0, W6 8PW. The official website for the company is www.achillestx.com. The company can be reached via phone at 44-0-20-8154-4600 or via email at ir@achillestx.com.